Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT ID: NCT05553093
Last Updated: 2022-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
150 participants
INTERVENTIONAL
2022-03-15
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
NCT00212290
Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus
NCT05360147
Liraglutide and Heart Failure in Type 2 Diabetes
NCT01425580
Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes
NCT01206322
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tirzepatide
Tirzepatide 5、10、15mg
Tirzepatide
Tirzepatide ih qw
Insulin Glargine
Insulin Glargine 6 international unit (IU)
Insulin Glargine
6 IU ih qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
Tirzepatide ih qw
Insulin Glargine
6 IU ih qd
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received stable metformin with or without sulfonylureas at least 2 months prior to visit 1 and between visits 1 and 3 (metformin ≥ 1000 mg/ day and does not exceed the maximum dose specified in the nationally approved guidelines;Sulfonylureas should be at least half of the maximum dose as stated in the national approved instructions).
* No insulin treatment (except for gestational diabetes or short-term use in acute Settings \[duration ≤14 days\]).
* At visit 1, HbA1c ≥ 7.5% and ≤ 11.0% was determined according to the central laboratory.
* Body mass index (BMI) ≥ 23 kg/m2.
Exclusion Criteria
* Had chronic or acute pancreatitis at any time prior to visit 1.
* A history of proliferative diabetic retinopathy or diabetic macular degeneration or non-proliferative diabetic retinopathy requiring acute treatment.
* History of severe hypoglycemia and/or insensitive hypoglycemia within 6 months prior to visit 1.
* History of ketoacidosis or hyperosmolar state/coma
* Have a known clinically significant gastric emptying disorder (e.g., severe diabetic gastroparesis or gastric outlet obstruction), have received or plan to undergo gastric bypass surgery or restrictive bariatric surgery (e.g., Lap-Band®) during the study period, or take long-term medications that directly affect gastrointestinal motility.
* Had any of the following cardiovascular diseases in the 2 months prior to the visit: acute myocardial infarction or cerebrovascular accident (stroke) or hospitalization due to congestive heart failure (CHF).
* New York Heart Association Classification of Heart Function Class III and Class IV CHF.
* Have acute or chronic hepatitis, have signs or symptoms of any liver disease other than non-alcoholic fatty liver disease (NAFLD), or have alanine aminotransferase (ALT) levels \> 3.0 times the upper limit of the normal range determined by the central laboratory at visit 1;For NAFLD patients, only ALT levels ≤ 3.0 times the upper limit of the normal range (ULN) were eligible for this trial.
* The estimated glomerular filtration rate (eGFR) calculated based on the Chronic Kidney Disease Epidemiology Collaboration equation（CKD-EPI）formula was less than 45 mL/min/1.73 m2, as determined by the central laboratory at visit 1.
* The researchers suggest that there is evidence of significant, poorly controlled endocrine abnormalities, such as thyrotoxicosis or adrenal crisis.
* Family or personal history of medullary thyroid cancer (MTC) or type 2 multiple endocrine tumor syndrome.
* Serum calcitonin level ≥ 35 ng/L (pg/mL) was determined by the central laboratory at visit 1.
* There was significant evidence of active autoimmune abnormalities (e.g., lupus or rheumatoid arthritis) and the investigators suggested that systemic glucocorticoid therapy might be required in the following 12 months.
* Has received an organ transplant (corneal transplant allowed) or is waiting for an organ transplant.
* A history of active or untreated malignancy, or a remission period of less than 5 years for a clinically significant malignancy (other than basal or squamous cell skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the prostate).
* Presence of any other medical history (e.g., known drug or alcohol abuse or mental illness) that the investigator considered would have prevented the patient from complying with and completing the study protocol.
* Presence of any blood disorders that may interfere with HbA1c measurements (e.g., hemolytic anemia, sickle cell disease).
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanjing First Hospital, Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianhua Ma, Doctor
Role: STUDY_DIRECTOR
The First Affiliated Hospital with Nanjing Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanjing First Hospital
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KY20220124-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.